You may have noticed that we like rankings and lists here at FiercePharma. Usually we like to do our own, but we also pass along other people's interesting work. This time, Motley Fool has done some serious math to peg the 15 most undervalued companies in biopharma.
We'll let them explain the methodology; suffice it to say here that it's basically about P/E ratios. As the Fool notes, a plethora of studies have shown that stocks with low P/Es outperform those with high P/Es. The drugmakers that fit the bill include Endo Pharmaceuticals, which tops the list and boasts a P/E of 7.5 and estimated EPS growth of 10 percent.
Rounding out the top five are Gilead Sciences (P/E of 9.7; EPS growth 14 percent); Merck (P/E 10.4; EPS 7 percent); Amgen (P/E 10.7; EPS 9 percent); and Teva Pharmaceutical (P/E 11; EPS growth 13 percent). Abbott Laboratories and Johnson & Johnson also make an appearance on the list.
- read the Motley Fool article